Regeneron's higher-dose Eylea is rejected by the FDA.

Published Date: 01 Jul 2023

On Tuesday, US health regulators decided against approving a higher dosage of Regeneron's drug Eylea for the treatment of a condition that is the primary cause of blindness in the elderly.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

2.

Chemo causes lasting physical decline in breast cancer survivors

3.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

4.

Race, Geography Linked to Gaps in Prostate Cancer Care

5.

DNA origami offers more accurate imaging in the fight against pancreatic cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot